Is CORT or CRBP more undervalued in 2026?

CirclFi compares Corcept Therapeutics Incorporat (CORT) and Corbus Pharmaceuticals Holdings (CRBP) using 13 institutional-grade valuation models. CORT has a Quality of Company score of 8.7/10 while CRBP scores 3.8/10.

Which is a better buy — CORT or CRBP?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CORT and CRBP valuations compare?

CORT at $68.38 and CRBP at $7.64 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CORT vs CRBP Valuation Comparison 2026 — Intrinsic Value Analysis

CORT

Biotechnology

Corcept Therapeutics Incorporat

Quality

8.7

out of 10

Value Trap

LOW

Price

$68.38

Last close

Models

13/13

Active

CRBP

Biotechnology

Corbus Pharmaceuticals Holdings

Quality

3.8

out of 10

Value Trap

SAFE

Price

$7.64

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	CORT Fair Value	CORT Upside	CRBP Fair Value	CRBP Upside
Bayesian DCF	Intrinsic	$15.47	-77.4%	$3.01	-60.6%
Earnings Power Value	Intrinsic	$8.28	-83.9%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$4.83	-92.9%	$8.57	+12.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CORT vs CRBP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CORT vs CRBP — Which Stock Is More Undervalued?

CORT scores higher with a 8.7/10 quality rating vs CRBP's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Corcept Therapeutics Incorporat (CORT) and Corbus Pharmaceuticals Holdings (CRBP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CORT currently trades at $68.38 with a QOC of 8.7/10, while CRBP trades at $7.64 with a QOC of 3.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).